Novartis Contract Manufacturing

Morris Plains, NJ · Stein, CH
Find alternatives to Novartis Contract Manufacturing for CAR-T →
Hybrid — also manufactures internal programs
421 confirmed programs · 118 sponsors · Last scored 2026-11-02
81.4
Signal Score
✓ FDA Inspections (19) ✓ Clinical Trials (284) ✓ SEC Filings (35) ✓ Press (20) ✓ EMA GMP (50) ✓ MHRA GMP (1) ✓ HC GMP (36)

Quick Facts: Novartis Contract Manufacturing

Signal Score
81.4/100 (as of 2026-11-02)
Quality Compliance
97.4/100 — Clean EMA record: 50 active GMP certificates (no deductions)
Headquarters
Morris Plains, NJ · Stein, CH
Modalities
CAR-T
Active Programs
421 confirmed from ClinicalTrials.gov across 118 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Novartis Contract Manufacturing

Hybrid developer + CDMO.

Signal Score & Pillar Breakdown

Quality Compliance 97.4
Clean EMA record: 50 active GMP certificates (no deductions)
Sources: FDA Data Dashboard, EMA EudraGMDP, MHRA GMDP
Clean EMA record: 50 active GMP certificates (no deductions)
FDA Inspections19 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2025-07-11)
EMA GMP Certificates50 on record
MHRA GMP Certificates1 on record
Most Recent HC OutcomeCompliant · 2025-12-18
HC Attribution36 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Clean EMA record: 50 active GMP certificates (no deductions)
Operations 94.7
421 active programs across 118 sponsors
Modalities: CAR-T
280 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
421 active programs across 118 sponsors · Modalities: CAR-T · 280 programs in advanced phases (Phase 2/3)
Programs 421
Sponsors118
ModalitiesCAR-T
421 active programs across 118 sponsors
Modalities: CAR-T
280 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07737756 A Real-World Medical Chart Review of Spinal Muscular Atrophy... NA Not Yet Recruiting
NCT07421167 A Study to Assess the Tolerability of Ianalumab (VAY736) With... PHASE2 Recruiting
NCT07621809 Two Arm, Double-blind, Phase III Study Assessing Efficacy and... PHASE3 Recruiting
NCT07448610 ASsessing The REAl-world Safety & Effectiveness of Spinal... PHASE4 Not Yet Recruiting
NCT07039422 Study of Ianalumab in Adults With Primary Immune... PHASE2 Recruiting
NCT07564401 A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy PHASE1/PHASE2 Recruiting
NCT07660055 Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients... PHASE1 Recruiting
NCT07468071 Rollover Study for Participants Who Have Been Treated With... PHASE1/PHASE2 Recruiting
NCT07378969 A Non-Interventional Study PASS to Characterize Secondary... NA Recruiting
NCT07006727 Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced... PHASE1 Recruiting
View all 284 programs →
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
35 SEC filings with industry mentions on record (shown, not scored)
SEC Filings35 with industry mentions (not scored)
Private company
Financial assessment: 60.0/100
Capacity 58.0
2 manufacturing sites
Sites: Morris Plains, NJ, Stein, CH
Source: company profiles (manufacturing sites, modality breadth)
2 manufacturing sites
StatusConstrained
2 manufacturing sites
Sites: Morris Plains, NJ, Stein, CH
Press Signals20 articles (not scored)
2 manufacturing sites

Novartis Contract Manufacturing FDA Inspection History

2025-07
2023-08
2026-06
2025-12
2025-12
2025-06
2025-03
2024-11
2024-08
2024-08
2024-06
2024-06
2024-02
2023-08
2023-06
2023-01
2022-12
2022-09
2022-08
NAI VAI OAI
Date Site Type 483 citations posted Classification
2025-07-11
Novartis Pharmaceuticals S.R.L.
Targu Mures Company-level
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2023-08-26
Novartis Pharmaceuticals S.R.L.
Targu Mures Company-level
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2026-06-24
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey Company-level
Bioresearch Monitoring Not posted No Action Indicated (NAI)
2025-12-18
Novartis Pharma AG
Basel Town Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2025-12-09
Novartis d.o.o.
Ljubljana Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2025-06-25
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey Company-level
Bioresearch Monitoring Not posted No Action Indicated (NAI)
2025-03-03
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey Company-level
Drug Quality Assurance Not posted No Action Indicated (NAI)
2024-11-19
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey Company-level
Bioresearch Monitoring Not posted No Action Indicated (NAI)
2024-08-29
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey Company-level
Bioresearch Monitoring Not posted No Action Indicated (NAI)
2024-08-08
Novartis Pharmaceuticals Corporation
Morris Plains, New Jersey Company-level
Human Cellular, Tissue, and Gene Therapies Yes Voluntary Action Indicated (VAI)
2024-06-27
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey Company-level
Bioresearch Monitoring Not posted No Action Indicated (NAI)
2024-06-04
Novartis Pharma AG
Basel Company-level
Bioresearch Monitoring Not posted No Action Indicated (NAI)
2024-02-09
Novartis d.o.o.
Ljubljana Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2023-08-21
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey Company-level
Bioresearch Monitoring Yes Voluntary Action Indicated (VAI)
2023-06-13
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey Company-level
Bioresearch Monitoring Not posted No Action Indicated (NAI)
2023-01-25
Novartis d.o.o.
Ljubljana Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2022-12-09
Novartis Pharmaceuticals Corporation
Morris Plains, New Jersey Company-level
Human Cellular, Tissue, and Gene Therapies Not posted Voluntary Action Indicated (VAI)
2022-09-21
Novartis d.o.o.
Menges Company-level
Drug Quality Assurance Not posted No Action Indicated (NAI)
2022-08-30
Novartis Pharma AG
Basel Town Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
Source: FDA Data Dashboard · Retrieved Nov 21, 2026

Novartis Contract Manufacturing FDA 483 Findings 5 observations · 2023-08-21 → 2024-08-08 ?

By subsystem

  • Documentation & Records 2 (40.0%)
  • Other 1 (20.0%)
  • Laboratory Controls 1 (20.0%)
  • Data Integrity 1 (20.0%)

By severity

  • 5 — Critical: 1
  • 3 — Moderate: 1
  • 2 — Minor: 3
  • Repeat observations: 0

Most severe findings

  • Critical (5) Data Integrity 2024-08-08 21 CFR 211.68(b)
    Computer control of master formula records

    "Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel."

  • Moderate (3) Laboratory Controls 2024-08-08 21 CFR 211.160(b)
    Scientifically sound laboratory controls

    "Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, sampling plans and test procedures designed to assure that components, drug product containers, closures, in-process materials and drug products conform to appropriate standards of identity, strength, quality and purity."

  • Minor (2) Documentation & Records 2024-08-08 21 CFR 211.22(d)
    Procedures not in writing, fully followed

    "The responsibilities and procedures applicable to the quality control unit are not fully followed."

Novartis Contract Manufacturing EMA GMP Compliance 50 certificates

2026-04
2026-04
2026-03
2026-03
2026-02
2026-01
2025-12
2025-12
2025-12
2025-12
2025-12
2025-12
2025-12
2025-12
2025-12
2025-12
2025-12
2025-12
2025-12
2025-11
2025-11
2025-11
2025-11
2025-10
2025-10
2025-10
2025-10
2025-10
2025-10
2025-10
2025-10
2025-10
2025-10
2025-04
2025-04
2024-11
2024-09
2023-12
2023-12
2023-12
2023-12
2023-12
2023-12
2023-12
2023-12
2023-12
2023-12
2023-06
2023-02
2023-02
Compliant Non-Compliant
Certificate Site Country Inspection Date Status
sukls112553/2026 Novartis s.r.o. Czechia 2026-04-15 COMPLIANT
sukls112575/2026 Novartis s.r.o. Czechia 2026-04-14 COMPLIANT
BE/GMP/2026/031 Novartis ManufacturingAlternative Name:Novartis Manufacturing N.V. Belgium 2026-03-18 COMPLIANT
484341-105007650 Novartis Pharmaceutical Manufacturing GmbH Austria 2026-03-17 COMPLIANT
DE_BY_05_GMP_2026_0054 Novartis Pharma GmbH Germany 2026-02-10 COMPLIANT
IT/90/H/2026 Novartis Farma S.p.A. Italy 2026-01-16 COMPLIANT
450-8/2026-2 Novartis Pharmaceutical Manufacturing LLCAlternative Name:Novartis farmacevtska proizvodnja d.o.o. Slovenia 2025-12-19 COMPLIANT
450-15/2026-2 Novartis Pharmaceutical Manufacturing LLCAlternative Name:Novartis farmacevtska proizvodnja d.o.o. Slovenia 2025-12-19 COMPLIANT
450-16/2026-2 Novartis Pharmaceutical Manufacturing LLCAlternative Name:Novartis farmacevtska proizvodnja d.o.o. Slovenia 2025-12-19 COMPLIANT
25/23121-34 Novartis Norge AS Norway 2025-12-10 COMPLIANT
401-27/2025-8 Novartis Pharmaceutical Manufacturing LLCAlternative Name:Novartis farmacevtska proizvodnja d.o.o. Slovenia 2025-12-09 COMPLIANT
450-15/2026-1 Novartis Pharmaceutical Manufacturing LLCAlternative Name:Novartis farmacevtska proizvodnja d.o.o. Slovenia 2025-12-09 COMPLIANT
450-16/2026-1 Novartis Pharmaceutical Manufacturing LLCAlternative Name:Novartis farmacevtska proizvodnja d.o.o. Slovenia 2025-12-09 COMPLIANT
484326-105148947 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-12-05 COMPLIANT
484326-103675833 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-12-05 COMPLIANT
484296-103675257 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-12-04 COMPLIANT
484296-105553013 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-12-04 COMPLIANT
484296-105579653 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-12-04 COMPLIANT
484296-105654285 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-12-04 COMPLIANT
BE/GMP/2025/157 Novartis PharmaAlternative Name:Novartis Pharma N.V. Belgium 2025-11-24 COMPLIANT
BE/GMP/2025/156 Novartis PharmaAlternative Name:Novartis Pharma N.V. Belgium 2025-11-24 COMPLIANT
BE/GMP/2025/206 Novartis PharmaAlternative Name:Novartis Pharma N.V. Belgium 2025-11-24 COMPLIANT
BE/GMP/2025/207 Novartis PharmaAlternative Name:Novartis Pharma N.V. Belgium 2025-11-24 COMPLIANT
484600-104544504 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-10-20 COMPLIANT
484600-105471718 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-10-20 COMPLIANT
DE_BY_05_GMP_2026_0024 Novartis Pharma GmbH Germany 2025-10-14 COMPLIANT
484295-104642509 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-10-10 COMPLIANT
484295-103675105 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-10-10 COMPLIANT
484295-104295901 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-10-10 COMPLIANT
484295-105471003 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-10-10 COMPLIANT
484295-105582044 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-10-10 COMPLIANT
484295-105600304 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-10-10 COMPLIANT
484295-105619677 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-10-10 COMPLIANT
401-7/2025-5 Novartis Pharmaceutical Manufacturing LLC Slovenia 2025-04-10 COMPLIANT
450-16/2026-3 Novartis Pharmaceutical Manufacturing LLC Slovenia 2025-04-10 COMPLIANT
484496-103501763 Novartis Pharmaceutical Manufacturing GmbH Austria 2024-11-04 COMPLIANT
450-4/2025-1 Novartis Pharmaceutical Manufacturing LLC Slovenia 2024-09-20 COMPLIANT
484295-102362426 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-12-14 COMPLIANT
484295-104659277 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-12-14 COMPLIANT
484295-103890257 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-12-14 COMPLIANT
484295-104484889 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-12-14 COMPLIANT
484295-102504807 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-12-14 COMPLIANT
484295-104299099 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-12-14 COMPLIANT
484295-104466717 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-12-14 COMPLIANT
484295-104090448 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-12-14 COMPLIANT
484295-102485983 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-12-14 COMPLIANT
484295-102771143 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-12-14 COMPLIANT
484341-101944492 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-06-27 COMPLIANT
484296-103654468 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-02-15 COMPLIANT
484326-101544917 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-02-13 COMPLIANT
Source: EMA EudraGMDP · Retrieved Nov 21, 2026

Novartis Contract Manufacturing MHRA GMP Compliance 1 certificates

2013-04
Compliant Non-Compliant
Certificate Site City / Postcode Inspection Date Status
UK GMP 4647 Insp GMP 4647/1766568-0003[H] NOVARTIS 94070-06256 2013-04-22 COMPLIANT
Source: MHRA GMDP Database · Retrieved Nov 21, 2026

Japan-accredited overseas site (PMDA)

sterile, biologics, general (non-sterile), packaging/storage only, CGT packaging/storage only · 5 sites · own products, not contract-manufacturing evidence

  • Langkampfen, Austria · Novartis Pharmaceutical Manufacturing GmbH — sterile, biologics, packaging/storage only, CGT packaging/storage only · valid to Jun 30, 2028
  • Puurs-Sint-Amands, Belgium · Novartis Manufacturing NV — sterile · valid to Oct 27, 2029
  • Romania · Novartis Pharmaceuticals S.r.l. — general (non-sterile) · valid to Aug 31, 2030
  • Ljubljana, Slovenia · Novartis Pharmaceutical Manufacturing LLC — sterile, general (non-sterile) · valid to Jul 2, 2028
  • Menges, Slovenia · Novartis Pharmaceutical Manufacturing LLC — biologics, general (non-sterile) · valid to Jul 2, 2028

PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. These approvals cover the company's own products; they are not evidence of contract manufacturing. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)

Clinical Activity 284 studies

NCT07737756 A Real-World Medical Chart Review of Spinal Muscular Atrophy Patients... NA Not Yet Recruiting NCT07421167 A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's... PHASE2 Recruiting NCT07621809 Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of... PHASE3 Recruiting NCT07448610 ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy... PHASE4 Not Yet Recruiting NCT07039422 Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and... PHASE2 Recruiting NCT07564401 A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy PHASE1/PHASE2 Recruiting NCT07660055 Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors PHASE1 Recruiting NCT07468071 Rollover Study for Participants Who Have Been Treated With and Are... PHASE1/PHASE2 Recruiting NCT07378969 A Non-Interventional Study PASS to Characterize Secondary Malignancies of... NA Recruiting NCT07006727 Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing... PHASE1 Recruiting NCT06855277 Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants... PHASE3 Recruiting NCT07048197 A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of... PHASE1/PHASE2 Active Not Recruiting NCT07029555 An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis PHASE1 Active Not Recruiting NCT06910813 DFT383 in Pediatric Participants With Nephropathic Cystinosis PHASE1/PHASE2 Recruiting NCT06711887 Phase III Extension Study of Efficacy and Safety of Ianalumab With or... PHASE3 Recruiting NCT06704269 Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in... PHASE1/PHASE2 Active Not Recruiting NCT06726148 Study of ECI830 Single Agent or in Combination in Patients With Advanced... PHASE1/PHASE2 Recruiting NCT06868290 Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe... PHASE2 Active Not Recruiting NCT06617793 An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of... PHASE1/PHASE2 Active Not Recruiting NCT06665256 Phase 2 Study of Rapcabtagene Autoleucel in Myositis PHASE2 Active Not Recruiting
+ 264 more studies
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No count for this company yet. The careers board we can read covers more than this business (100 postings on Nov 20, 2026), and we can't yet tell which of those roles belong to it. Why: the group's board only shows its ~100 newest postings across all units, so we can't separate this business's roles. We'd rather show no number than one that isn't really this company's.
Source: novartis.wd3.myworkdayjobs.com · Checked Nov 20, 2026

Financial Intelligence

6-K 2026-09-08 0 keyword mentions
6-K 2026-09-04 0 keyword mentions
6-K 2026-09-01 0 keyword mentions
6-K 2026-07-21 0 keyword mentions
6-K 2026-06-11 1 keyword mentions
"These results validate the dosing regimen implemented in our Phase III trial and lend further evidence of the potential for del-brax to have a significant impact for people with FSHD,” said Nazem Atassi, Global Head, Neuroscience and Gene Therapy Development, Novartis."
6-K 2026-04-28 0 keyword mentions
6-K 2026-03-18 0 keyword mentions
6-K 2026-02-04 0 keyword mentions
6-K 2026-02-04 0 keyword mentions
20-F 2026-02-04 24 keyword mentions
"We face a challenge to attract and retain top talent in several areas, including biology, immunology, chemistry, clinical development, drug manufacturing, data, digital and IT, including AI, oncology, and advanced therapy platforms (i.e., gene and cell therapy, radioligand therapy, and xRNA)."
"In addition, we manufacture and sell a number of sterile products, biologic products, and products that involve advanced therapy platforms, such as gene and cell therapy, radioligand therapy, and xRNA, or require a supply of highly specialized raw materials, such as cell lines, tissue samples, bacteria, viral strains, and radioisotopes."
"The T315I mutation causes resistance to most available TKI therapies, and, as a result, patients with this mutation would otherwise have limited treatment options • Zolgensma (onasemnogene abeparvovec)/ Itvisma (onasemnogene abeparvovec-brve) is a one-time gene therapy designed to address the genetic root cause of spinal muscular atrophy (SMA) by replacing the function of the missing or nonworking SMN1 gene."
6-K 2025-11-25 5 keyword mentions
"“The SMA disease landscape has dramatically changed over the last six years, when the first gene therapy was approved."
"Novartis has an exclusive, worldwide license with Nationwide Children's Hospital to both the intravenous and intrathecal delivery of adeno-associated virus 9 (AAV9) gene replacement therapy for the treatment of all types of SMA; an exclusive, worldwide license from REGENXBIO for any recombinant AAV vector in its intellectual property portfolio for the in vivo gene replacement therapy treatment of SMA in humans; an exclusive, worldwide licensing agreement with Généthon for in vivo delivery of AAV"
6-K 2025-11-20 0 keyword mentions
6-K 2025-11-05 0 keyword mentions
6-K 2025-10-28 0 keyword mentions
6-K 2025-10-27 0 keyword mentions
6-K 2025-09-30 0 keyword mentions
6-K 2025-08-11 0 keyword mentions
6-K 2025-07-17 0 keyword mentions
6-K 2025-07-17 0 keyword mentions
6-K 2025-06-02 0 keyword mentions
6-K 2025-04-29 0 keyword mentions
6-K 2025-04-03 0 keyword mentions
6-K 2025-03-28 0 keyword mentions
6-K 2025-01-31 0 keyword mentions
6-K 2025-01-31 0 keyword mentions
20-F 2025-01-31 28 keyword mentions
"We face a challenge to attract and retain top talent in several areas, including biology, immunology, chemistry, clinical development, drug manufacturing, data, digital and IT, oncology, and advanced therapy platforms (i.e., gene and cell therapy, radioligand therapy and xRNA) and to maintain and strengthen our employer reputation."
"In addition, we manufacture and sell a number of sterile products, biologic products and products that involve advanced therapy platforms, such as gene and cell therapy, radioligand therapy, and xRNA, all of which are particularly complex and involve highly specialized manufacturing technologies."
"In addition, we manufacture and sell a number of sterile products, biologic products, and products that involve advanced therapy platforms, such as gene and cell therapy, radioligand therapy, and xRNA, all of which are particularly complex and involve highly specialized manufacturing technologies."
6-K 2024-12-30 10 keyword mentions
"OAV101 IT is the first investigational gene therapy to provide clinical benefit in treatment-naïve patients with SMA aged two and older with a positive risk benefit profile"
"7 The results from the Phase III STEER study add to the clinical data and emerging real-world evidence for the use of one-time gene therapy to treat SMA."
"About OAV101 IT Intrathecal onasemnogene abeparvovec (OAV101 IT) is an investigational, one-time gene therapy for patients with spinal muscular atrophy (SMA)."
6-K 2024-11-25 0 keyword mentions
6-K 2024-10-29 0 keyword mentions
6-K 2024-10-29 0 keyword mentions
6-K 2024-09-18 0 keyword mentions
6-K 2024-09-17 0 keyword mentions
6-K 2024-08-08 0 keyword mentions
6-K 2024-07-18 0 keyword mentions
6-K 2024-04-23 0 keyword mentions
Source: SEC EDGAR · Retrieved Nov 21, 2026

Company Signals 20 articles

Company announcements, not verified evidence. They do not change any score.
general 2026-05-06
Novartis Plans Closure Of Wehr Manufacturing Site By 2028 - RTTNews
Novartis Plans Closure Of Wehr Manufacturing Site By 2028  RTTNews
general 2026-05-05
Novartis to close German manufacturing site, cutting 220 jobs - Fierce Pharma
Novartis to close German manufacturing site, cutting 220 jobs  Fierce Pharma
facility_expansion 2026-05-05
Novartis to site seventh new facility in North Carolina - European Pharmaceutical Review
Novartis to site seventh new facility in North Carolina  European Pharmaceutical Review
general 2026-05-05
Biopharma bites: FDA withholds vaccine data, plus staffing cuts for Novartis, Gilead - FirstWord Pharma
Biopharma bites: FDA withholds vaccine data, plus staffing cuts for Novartis, Gilead  FirstWord Pharma
facility_expansion 2026-05-04
Novartis to Add New Facility in Morrisville, NC - Contract Pharma
Novartis to Add New Facility in Morrisville, NC  Contract Pharma
general 2026-05-03
Novartis taps North Carolina as new manufacturing hub location - MSN
Novartis taps North Carolina as new manufacturing hub location  MSN
facility_expansion 2026-05-01
Novartis unveils North Carolina API plant as final piece of $23B US expansion - BioSpace
Novartis unveils North Carolina API plant as final piece of $23B US expansion  BioSpace
general 2026-04-30
Novartis rounds out $23B US investment push with plans for North Carolina API plant - Fierce Pharma
Novartis rounds out $23B US investment push with plans for North Carolina API plant  Fierce Pharma
general 2026-04-30
Novartis to build Morrisville pharma facility as part of $23 billion push - CBS 17
Novartis to build Morrisville pharma facility as part of $23 billion push  CBS 17
facility_expansion 2026-04-30
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility - GlobeNewswire
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility  GlobeNewswire
facility_expansion 2026-04-30
Novartis unveils North Carolina factory as final new build in $23B US expansion - Endpoints News
Novartis unveils North Carolina factory as final new build in $23B US expansion  Endpoints News
general 2026-04-30
Novartis announces new API manufacturing facility in North Carolina - StreetInsider
Novartis announces new API manufacturing facility in North Carolina  StreetInsider
facility_expansion 2026-04-30
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility - marketscreener.com
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility  marketscreener.com
general 2026-04-30
Novartis to open new drug manufacturing facility in Morrisville, North Carolina - ABC11 Raleigh-Durham
Novartis finalizes new drug manufacturing facility in Morrisville, North Carolina  ABC11 Raleigh-Durham
facility_expansion 2026-04-30
Novartis finalizes US manufacturing and R&D expansion plan - The Pharma Letter
Novartis finalizes US manufacturing and R&D expansion plan  The Pharma Letter
facility_expansion 2026-04-30
Novartis (NVS) Expands Manufacturing with New Facility in North Carolina - GuruFocus
Novartis (NVS) Expands Manufacturing with New Facility in North Carolina  GuruFocus
general 2026-04-30
Novartis to build Morrisville pharma facility as part of $23 billion push - CBS 17
Novartis to build Morrisville pharma facility as part of $23 billion push  CBS 17
general 2026-04-30
Manufacturing Insights: Novartis’ Next Move - DCAT Value Chain Insights
Manufacturing Insights: Novartis’ Next Move  DCAT Value Chain Insights
general 2026-04-30
Novartis to open API manufacturing facility in Morrisville - BioProcess International
Novartis to open API manufacturing facility in Morrisville  BioProcess International
facility_expansion 2026-04-30
Novartis Finalizes US Expansion with Seventh Facility to Strengthen End-to-End Drug Manufacturing - BioPharm International
Novartis Finalizes US Expansion with Seventh Facility to Strengthen End-to-End Drug Manufacturing  BioPharm International

Frequently Asked Questions About Novartis Contract Manufacturing

How many FDA inspections does Novartis Contract Manufacturing have on record?
CDMO Signal tracks 19 FDA inspections for Novartis Contract Manufacturing, sourced from the FDA inspection database. See the full inspection history above.
Has Novartis Contract Manufacturing received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Novartis Contract Manufacturing.
Does Novartis Contract Manufacturing hold EMA or MHRA GMP certificates?
CDMO Signal tracks 50 EMA and 1 MHRA GMP certificates for Novartis Contract Manufacturing.
How many clinical programs is Novartis Contract Manufacturing linked to?
Novartis Contract Manufacturing is associated with 284 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Novartis Contract Manufacturing's CDMO Signal Score?
Novartis Contract Manufacturing has a Signal Score of 81/100, based on quality, operations, financial stability, and capacity data.
Evaluating Novartis Contract Manufacturing for a manufacturing program?
Use the free AI matchmaker to compare Novartis Contract Manufacturing against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs →

Similar CDMOs

Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 87.0
CAR-T, Cell Therapy
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.1
CAR-T, Cell Therapy
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 82.7
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 79.9
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation

Compare Novartis Contract Manufacturing with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Novartis Contract Manufacturing
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.